National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Read this book online, free! Click here to proceed to linked table of contents

Safe and Effective Medicines for Children:

Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act

Book Cover

Status: Available Now

Size: 408 pages, 6 x 9

Publication Year:2012


E-mail this page
Print List Price    
Order online and save 10%
PAPERBACK
ISBN-10: 0-309-22549-3
ISBN-13: 978-0-309-22549-6
$65.00   Add to Cart
PDF     About PDF

Authors:
Marilyn J. Field and Thomas F. Boat, Editors; Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA); Institute of Medicine
Authoring Organizations

Description:

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in ...
Read More


Paste into your Web page:

Preview
Free Resources
Read

Full Text
Jump to this book's table of contents to begin reading online for free.

Research Tools
Download Free

PDF Summary
Download the summary in PDF.

Rights & Permissions

Reprint Permission
Request permission to license or reprint the book's content through Copyright Clearance Center's Rightslink.

Request Permission to Distribute a PDF

Request Translation Rights

Questions About Rights and Permissions?

Description

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.

Search This Book

»Find more like this book

SIGN UP FOR...

New Title Emails
Read about the newest releases and receive special offers.